Although effectiveness was shown in patients with a range of levels of HER2 staining, NICE limited reimbursement ... as the presentations at ASCO revealed that PD-L1 activity correlates with ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster ...

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

Relationship between PD-L1 expression and the number of biopsy specimens in advanced gastric cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...

Strong membrane staining in the normal epithelial ... This principle is indeed used in the algorithms for HER2 testing proposed by the ASCO/CAP guidelines. The preanalytical variants can similarly ...

Impact of expression of metabolic genes on patient (pts) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance). This is an ASCO Meeting Abstract from the 2025 ASCO ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

is presenting clinical data from a completed Phase 1 trial evaluating a novel autologous HER2-targeted CAR-T therapy. The data presented today at the ASCO Gastrointestinal Cancers Symposium ...